Psoriasis is an immune-mediated, inflammatory condition of the skin affecting nearly 3 % of the world’s population. As a chronic disease psoriasis has a substantial effect on the quality of life of patients. More than 80% of patients have mild to moderate psoriasis, for which topical therapies are first line of treatment. Patients with severe psoriasis are eligible for systemic therapies (orals and biologics), which are often used in combination with topicals
Aim of Wynzora® Cream
For patients suffering from plaque psoriasis the dual mode of action of calcipotriene and betamethasone dipropionate (“Calcipotriene/BDP”) provides fast relief of symptoms with just once daily application, while offering a favorable safety profile. Using PAD™ Technology Wynzora® Cream is the first and only aqueous and cream based formulation of Calcipotriene/BDP and is designed to be non-greasy and convenient in daily routines while providing effective relief of symptoms.
A new treatment experience for patients with plaque psoriasis.
US FDA approved on July 20th, 2020.
EU Ph3 successfully completed – MAA submitted in June 2020.
Active ingredients: Calcipotriene/betamethasone dipropionate
Indication: Plaque psoriasis